MX2015016670A - Proceso para preparar apolipoproteina a-i (apo- a-i). - Google Patents
Proceso para preparar apolipoproteina a-i (apo- a-i).Info
- Publication number
- MX2015016670A MX2015016670A MX2015016670A MX2015016670A MX2015016670A MX 2015016670 A MX2015016670 A MX 2015016670A MX 2015016670 A MX2015016670 A MX 2015016670A MX 2015016670 A MX2015016670 A MX 2015016670A MX 2015016670 A MX2015016670 A MX 2015016670A
- Authority
- MX
- Mexico
- Prior art keywords
- apo
- suspension
- processes
- containing protein
- protein fraction
- Prior art date
Links
- 102000005666 Apolipoprotein A-I Human genes 0.000 title abstract 7
- 108010059886 Apolipoprotein A-I Proteins 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000725 suspension Substances 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Water Supply & Treatment (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con procesos para obtener Apo A-I a partir de una Apo A-I que contiene una fracción (A) de proteína, que comprende suspender la Apo A-I que contiene la fracción (A) de proteína en una solución (B) de regularor, eliminar impurezas de la suspensión mientras mantiene las proteínas de Apo A-I solubilizada, seguido por la precipitación de Apo A-I a partir de la suspensión y recolectar el precipitación de Apo A-I a partir de la suspensión y recolectar el precipitado de Apo A-I. También se proporcionan la Apo A-I obtenida por tales procesos, el HDL reconstituido, obtenido de tal Apo A-I, y las composiciones farmacéuticas que comprenden tal Apo A-I y/o HDL reconstituido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831304P | 2013-06-05 | 2013-06-05 | |
| PCT/AU2014/000584 WO2014194362A1 (en) | 2013-06-05 | 2014-06-05 | Process for preparing apolipoprotein a-i (apo a-i) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016670A true MX2015016670A (es) | 2016-07-15 |
Family
ID=52007306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016670A MX2015016670A (es) | 2013-06-05 | 2014-06-05 | Proceso para preparar apolipoproteina a-i (apo- a-i). |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9890203B2 (es) |
| EP (2) | EP4209504A1 (es) |
| JP (1) | JP6404333B2 (es) |
| KR (1) | KR102275477B1 (es) |
| CN (2) | CN110172093A (es) |
| AU (1) | AU2014277617B2 (es) |
| CA (2) | CA3190893A1 (es) |
| DK (1) | DK3004160T3 (es) |
| ES (1) | ES2940304T3 (es) |
| HK (1) | HK1220210A1 (es) |
| IL (1) | IL242688B (es) |
| MX (1) | MX2015016670A (es) |
| NZ (1) | NZ631116A (es) |
| PL (1) | PL3004160T3 (es) |
| RU (1) | RU2668831C2 (es) |
| SG (3) | SG10201709820QA (es) |
| WO (1) | WO2014194362A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201709820QA (en) | 2013-06-05 | 2018-01-30 | Csl Ltd | Process for preparing apolipoprotein a-i (apo a-i) |
| CN109701004B (zh) | 2013-08-08 | 2022-11-08 | 杰特有限公司 | 去除污染物的方法 |
| CN110151972A (zh) * | 2018-02-11 | 2019-08-23 | 中国中医科学院中医基础理论研究所 | 基于多肽的重组高密度脂蛋白前体及其制备方法与应用 |
| WO2020160505A1 (en) * | 2019-02-01 | 2020-08-06 | Ohio State Innovation Foundation | Methods of protein purification |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| JP2001522349A (ja) * | 1996-08-23 | 2001-11-13 | エスペリオン セラピューティックス インコーポレイテッド | アポリポタンパク質ａまたはアポリポタンパク質ｅをヒト血漿から精製するためのプロセス |
| TW388763B (en) * | 1996-09-04 | 2000-05-01 | Rotkreuzstiftung Zentrallab | Method of producing a hyper immunoglobulin preparation from fractions produced druing fractionation of human blood plasma |
| CA2428114C (en) * | 2000-11-10 | 2013-07-23 | Proteopharma Aps | Apolipoprotein analogues |
| US7777006B2 (en) * | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| US20080176254A1 (en) * | 2003-07-14 | 2008-07-24 | Xiangming Fang | Affinity separation compositions and methods |
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| US8013122B2 (en) * | 2006-12-20 | 2011-09-06 | Kieu Hoang | Method of purifying apolipoprotein A-1 |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| CN101778860B (zh) | 2007-08-17 | 2013-07-10 | Csl百灵有限公司 | α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法 |
| US20110293557A1 (en) * | 2008-06-13 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| CN102127165B (zh) * | 2010-01-15 | 2013-09-04 | 上海莱士血液制品股份有限公司 | 一种从血浆组分四沉淀中制备高纯ApoA-I的生产工艺 |
| CN103118683B (zh) * | 2010-06-30 | 2015-08-19 | 杰特有限公司 | 重建高密度脂蛋白制剂及其生产方法 |
| CN102731642B (zh) * | 2011-04-14 | 2014-01-29 | 上海莱士血液制品股份有限公司 | 从人血浆组分四沉淀制备高纯Apoa-I的生产工艺 |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| SG10201709820QA (en) | 2013-06-05 | 2018-01-30 | Csl Ltd | Process for preparing apolipoprotein a-i (apo a-i) |
-
2014
- 2014-06-05 SG SG10201709820QA patent/SG10201709820QA/en unknown
- 2014-06-05 RU RU2015155602A patent/RU2668831C2/ru active
- 2014-06-05 WO PCT/AU2014/000584 patent/WO2014194362A1/en active Application Filing
- 2014-06-05 CA CA3190893A patent/CA3190893A1/en active Pending
- 2014-06-05 JP JP2016517095A patent/JP6404333B2/ja active Active
- 2014-06-05 DK DK14808213.4T patent/DK3004160T3/da active
- 2014-06-05 EP EP22213998.2A patent/EP4209504A1/en active Pending
- 2014-06-05 AU AU2014277617A patent/AU2014277617B2/en active Active
- 2014-06-05 CN CN201910247685.2A patent/CN110172093A/zh active Pending
- 2014-06-05 CA CA2914260A patent/CA2914260C/en active Active
- 2014-06-05 SG SG10201911705YA patent/SG10201911705YA/en unknown
- 2014-06-05 CN CN201480032030.9A patent/CN105339387B/zh active Active
- 2014-06-05 KR KR1020167000150A patent/KR102275477B1/ko active IP Right Grant
- 2014-06-05 US US14/893,178 patent/US9890203B2/en active Active
- 2014-06-05 EP EP14808213.4A patent/EP3004160B1/en active Active
- 2014-06-05 ES ES14808213T patent/ES2940304T3/es active Active
- 2014-06-05 NZ NZ631116A patent/NZ631116A/en unknown
- 2014-06-05 SG SG11201509565VA patent/SG11201509565VA/en unknown
- 2014-06-05 MX MX2015016670A patent/MX2015016670A/es unknown
- 2014-06-05 PL PL14808213.4T patent/PL3004160T3/pl unknown
-
2015
- 2015-11-19 IL IL242688A patent/IL242688B/en active IP Right Grant
-
2016
- 2016-07-13 HK HK16108249.4A patent/HK1220210A1/zh unknown
-
2018
- 2018-01-12 US US15/870,203 patent/US10421799B2/en active Active
-
2019
- 2019-09-18 US US16/575,105 patent/US11279750B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10288A (es) | ||
| MX349601B (es) | Remocion de virus contaminantes de preparaciones de aav. | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| MX2018002068A (es) | Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. | |
| CA2801536C (en) | Protein concentrates and isolates, and processes for the production thereof from macroalgae and/or microalgae | |
| JO3476B1 (ar) | بروتينات مندمجة لعلاج الاضطرابات الايضية | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
| MX2012007103A (es) | Solucion y metodo de lavado por cromatografia de afinidad. | |
| TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
| MX2017000773A (es) | Metodo para extraer proteinas solubles de biomasa de microalgas. | |
| MX2015016670A (es) | Proceso para preparar apolipoproteina a-i (apo- a-i). | |
| MX2019005999A (es) | Precipitacion de la fraccion i-iv-1 de inmunoglobulinas plasmaticas. | |
| SG10201807572PA (en) | Robust antibody purification | |
| MA37749B1 (fr) | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine | |
| MX340349B (es) | Metodo para la produccion de formulaciones inyectables de productos proteicos hemoderivados y productos obtenidos utilizando dicho método. | |
| MX2012010148A (es) | Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion. | |
| MX2016012428A (es) | Aumento de la expresion de proteina recombinante con cobre. | |
| SG11201902998SA (en) | PROMOTER OF Hspa5 GENE | |
| BR112016027818A2 (pt) | composições purificadas de proteínas ivig e kh para modular linfócitos e tratar virus da hepatite b. | |
| MX2020002552A (es) | Métodos y composiciones para preparar proteína surfactante d (sp-d). | |
| GB201118201D0 (en) | Novel peptides | |
| MX2020002551A (es) | Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d). | |
| MY188494A (en) | High-growth enterovirus 71 strains and vaccines | |
| MX2022002774A (es) | Método de captura y purificación de productos biológicos. |